Immunotherapy gives hope for the cure of cancer. However, the current immunotherapies only show efficacy in a small proportion of patients and is often associated with toxicities. Therefore, there is a need to investigate and develop novel immunotherapies. TIGIT and LFA-1 are molecules expressed on immune cells and they both play a role in regulating immune cell activation and responses to cancer. In this project, I will investigate the effects of simultaneously modulating the function of TIGIT and LFA-1 on immune cell properties including the ability to kill cancer cells. The safety of the combination therapy will also be investigated on the organismal level. I will use both mouse and human immune cells and various mouse tumor models in this study. The research will take place at the Viikki campus of the University of Helsinki

2025

2029